Drug intelligence / Profile preview

gallium-68 NOTA-pamidronic acid

Development stage
Preclinical
Lead developer
Universiti Putra Malaysia
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Small Molecules
Administration
Intravenous
01

Overview

Gallium-68 NOTA-pamidronic acid (also referred to as [68Ga]Ga-NOTA-pamidronic acid) is an investigational gallium-68-labeled bisphosphonate radiotracer developed for positron emission tomography (PET) imaging of the skeleton. It consists of pamidronic acid, a bisphosphonate with high affinity for hydroxyapatite in bone, conjugated to the bifunctional chelator NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid) and complexed with the positron-emitting radionuclide gallium-68. Preclinical studies demonstrate that the tracer exhibits favorable skeletal targeting with rapid renal clearance, making it a promising candidate for bone-targeted PET imaging, such as for the detection of bone metastases.

Other names
68Ga-NOTA-pamidronate68Ga-NOTA-pamidronic acid[68Ga]Ga-NOTA-pamidronate[68Ga]Ga-NOTA-pamidronic acidgallium-68 NOTA-pamidronategallium68 NOTA-pamidronategallium 68 NOTA-pamidronate
02

Identity

Drug type
Radiopharmaceuticals
Originator
Universiti Putra Malaysia
Modality
Small MoleculesAntibody-Based TherapeuticsAntibody-Radionuclide ConjugatesPositron Emitters
03

Pharmacology

Route
Intravenous
04

Development

IndicationHighest phaseStatus
bone metastasesPreclinicalActive
bone tumorsPreclinicalActive

Every indication, with countries and timelines, is in the full profile.

05

Regulatory

MarketStatusYear
United StatesNot approved—
European UnionNot approved—
ChinaNot approved—
JapanNot approved—

Approved indications and other markets are in the full profile.

06

Companies

  • Universiti Putra MalaysiaOriginator · Lead developer
07

Competitive landscape

Drugs on the same target
22
Drugs in the lead indication
60

Lead indication: bone metastases

Most advanced in the lead indication

  1. pamidronateApproved
  2. risedronateApproved
  3. alendronateApproved
  4. risedronate sodium delayed-releaseApproved
  5. Strontium chlorideApproved

Beyond the preview

Go deeper on gallium-68 NOTA-pamidronic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on gallium-68 NOTA-pamidronic acid.

Work on gallium-68 NOTA-pamidronic acid? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call